Literature DB >> 16984985

Association between neuromedin U gene variants and overweight and obesity.

Irena Hainerová1, Signe S Torekov, Jakob Ek, Marie Finková, Knut Borch-Johnsen, Torben Jørgensen, Ole D Madsen, Jan Lebl, Torben Hansen, Oluf Pedersen.   

Abstract

BACKGROUND: Neuromedin U (NMU) is an anorexic neuropeptide expressed in the hypothalamus. Mice lacking the NmU gene are hyperphagic and obese, whereas mice overexpressing Nmu are hypophagic and lean.
OBJECTIVE: Our objective was to investigate whether variants in NMU are associated with human obesity.
DESIGN: The coding region of NMU was analyzed for variants in obese Czech children and obese Danish adults. Identified missense variants were investigated for cosegregation with obesity in families or association with obesity in the general population.
SETTING: The study was performed at Steno Diabetes Center, Denmark, and Department of Pediatrics, Charles University, Czech Republic. SUBJECTS AND METHODS: A total of 289 Czech children and adolescents with early-onset obesity and 84 Danish obese adults were analyzed for variants in NMU. A NMU Ala19Glu polymorphism was genotyped in 5851 Danish subjects of the Inter99 cohort, and a rare NMU Arg165Trp mutation was sequenced in the proband family and in 53 lean and unrelated Czech subjects.
RESULTS: The rare NMU Arg165Trp variant cosegregated with childhood obesity in a Czech family. Homozygous carriers of the Glu allele of the NMU Ala19Glu polymorphism were more common in the overweight and obese subjects; the Glu/Glu frequency was 0.4 (95% confidence interval, 0.2-0.6) among 2586 lean subjects (BMI < 25 kg/m2) and 0.9 (95% confidence interval, 0.7-1.1) among 3265 overweight and obese subjects (body mass index >or= 25 kg/m2) [odds ratio, 2.5 (1.2-5.3); P = 0.01].
CONCLUSION: Amino acid variants in NMU associate with overweight and obesity, suggesting that NMU is involved in energy regulation in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984985     DOI: 10.1210/jc.2006-1442

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Neuromedin S and U.

Authors:  Colleen M Novak
Journal:  Endocrinology       Date:  2009-07       Impact factor: 4.736

Review 2.  Bone, brain & beyond.

Authors:  Alexandre Chamouni; Christiane Schreiweis; Franck Oury
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 3.  Peptides and their potential role in the treatment of diabetes and obesity.

Authors:  Hannah C Greenwood; Stephen R Bloom; Kevin G Murphy
Journal:  Rev Diabet Stud       Date:  2011-11-10

4.  Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.

Authors:  T Kaisho; H Nagai; T Asakawa; N Suzuki; H Fujita; K Matsumiya; N Nishizawa; Y Kanematsu-Yamaki; K Dote; J-I Sakamoto; T Asami; S Takekawa
Journal:  Int J Obes (Lond)       Date:  2017-07-31       Impact factor: 5.095

Review 5.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

Authors:  S S Torekov; L Ma; N Grarup; B Hartmann; I A Hainerová; U Kielgast; H Kissow; M Rosenkilde; J Lebl; D R Witte; T Jørgensen; A Sandbaek; T Lauritzen; O D Madsen; J Wang; A Linneberg; S Madsbad; J J Holst; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2011-08-07       Impact factor: 10.122

Review 7.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

8.  The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Authors:  Andrea Peier; Jennifer Kosinski; Kimberly Cox-York; Ying Qian; Kunal Desai; Yue Feng; Prashant Trivedi; Nicholas Hastings; Donald J Marsh
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

9.  Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity.

Authors:  Colleen M Novak; Minzhi Zhang; James A Levine
Journal:  Brain Res       Date:  2007-07-13       Impact factor: 3.252

10.  Appetite-modifying actions of pro-neuromedin U-derived peptides.

Authors:  David A Bechtold; Tina R Ivanov; Simon M Luckman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.